Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
United States
University of California, Los Angeles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles, California Sarah Cannon, SCRI Oncology Partners - Health One, Denver, Colorado Sarah Cannon, SCRI Oncology Partners, Nashville, Tennessee